GPT-Rosalind (OpenAI) vs OpenClaw

OpenClaw edges out GPT-Rosalind (OpenAI) by 0.8 points (7.6 vs 6.8) -- a B-tier vs C-tier split that's narrow but real. Not a blowout; both belong on a shortlist. The score gap shows up most clearly in the categories that matter for OpenClaw's strengths, so if those categories are your priority, the lead translates.

On pricing, OpenClaw starts free while GPT-Rosalind (OpenAI) requires a paid plan from day one (Invite only+). If you're testing the waters or running an occasional workload, that gap matters more than the score differential. GPT-Rosalind (OpenAI) starts at Invite only; OpenClaw starts at $0. Compare what each entry tier actually unlocks before you compare list prices -- the limits matter more than the headline number.

By use case: pick GPT-Rosalind (OpenAI) when researchers and enterprises in biology, drug discovery, protein science, translational medicine, or adjacent life-sciences domains who can get trusted access. Pick OpenClaw when technical users who will properly harden the deployment -- latest-patch version, firewall, no credentials with production write access, skill allow-list. The two tools aren't fighting for the same person -- they're aiming at adjacent jobs that occasionally overlap. If you're squarely in OpenClaw's lane, the tier-list ranking and the use-case fit point the same direction; if you're in GPT-Rosalind (OpenAI)'s lane, the score gap matters less than the fit.

Bottom line: OpenClaw is the safer default for most readers, but GPT-Rosalind (OpenAI) is competitive enough that the tie-breaker is your specific workload, not the spec sheet.